ReCor Medical, Inc. (“ReCor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., today announced late-breaking data from its RADIANCE II U.S. FDA IDE pivotal trial will be presented at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. ReCor will also have a symposium on the Paradise™ Ultrasound Renal Denervation (uRDN) System, two moderated posters and an exhibit at the conference. TCT will take place September 16-19, 2022, in Boston.
The details of the presentations are as follows:
Title: Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled RADIANCE II Pivotal Trial
Session: Late-Breaking Clinical Science in Vascular Disease and Hypertension: Session III, in Collaboration with The Journal of the American Medical Association
Presenter: Ajay J. Kirtane, MD, Columbia University Irving Medical Center
Location: Clinical Science & Endovascular Theater, Exhibition Level, Hall C, Boston Convention and Exhibition Center
Date and Time: Sunday, September 18, 2022; 11 AM EDT
Title: Ultrasound Renal Denervation (uRDN) – Leading with Evidence and Preparing for What Comes Next
Session: World Connect Theater Satellite Symposium
Moderator: Felix Mahfoud, MD, Saarland University Hospital, Homburg/Saar, Germany
Location: World Connect Theater, Exhibition Level, Hall C, Boston Convention and Exhibition Center
Date and Time: Monday, September 19, 2022; 12:15 PM EDT
Title: TCT 211: Home Blood Pressure Response to Ultrasound Renal Denervation – a Patient-level Pooled Analysis of the RADIANCE-HTN SOLO and TRIO Randomised, Sham-controlled Trials
Session: Hypertension and Renal Denervation
Presenter: Andrew Sharp, MD, University Hospital of Wales, Cardiff, UK
Location: Emerging Clinical Science & Research: Station 3, Exhibition Level, Hall C, Boston Convention and Exhibition Center
Date and Time: Saturday, September 17, 2022; 9 AM EDT
Title: TCT 212: Twenty-Four Month Results in Patients with Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial
Session: Hypertension and Renal Denervation
Presenter: Roland Schmieder, MD, University Hospital Erlangen, Erlangen, Germany
Location: Emerging Clinical Science & Research: Station 3, Exhibition Level, Hall C, Boston Convention and Exhibition Center
Date and Time: Saturday, September 17, 2022; 9:12 AM EDT
ReCor will also have a booth exhibit (#654) at the conference.
About ReCor Medical, Inc.
ReCor Medical, headquartered in Palo Alto, CA, a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., is a medical technology company focused on transforming the management of hypertension. ReCor has pioneered the use of the Paradise ultrasound renal denervation (uRDN) system for the treatment of hypertension. The Paradise System is an investigational device in the United States and bears the CE mark in the EU. ReCor has reported positive outcomes in three independent, randomized, sham-controlled studies of the Paradise System in patients with mild-to-moderate and resistant hypertension and plans to submit results of its RADIANCE Global Program as part of a PMA to the US FDA for market approval. In addition, ReCor has initiated the Global Paradise System (“GPS”) Registry in the EU with plans to expand on a global basis.
About Otsuka Medical Devices Co., Ltd.
Otsuka Medical Devices focuses on the global development and commercialization of medical care products including endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices Co., Ltd. is a subsidiary of Otsuka Holdings Co., Ltd. (www.otsuka.com/en), a global healthcare company listed on the Tokyo Stock Exchange (JP 4578).
Contacts
Annika Parrish
Health+Commerce
annika@healthandcommerce.com
